OBIO NASDAQ
Orchestra BioMed Holdings, Inc.
1W: +0.0%
1M: +20.2%
3M: +45.8%
YTD: +38.0%
1Y: +133.3%
3Y: -25.0%
5Y: -40.1%
$5.95
-0.40 (-6.30%)
Weekly Expected Move ±8.8%
$5
$5
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (29)
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Bank of New York Mellon Corp Makes New $372,000 Investment in Orchestra BioMed Holdings, Inc. $OBIO
BlackRock Inc. Makes New $10.83 Million Investment in Orchestra BioMed Holdings, Inc. $OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed GAAP EPS of -$0.38
Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO
12 Health Care Stocks Moving In Wednesday's After-Market Session
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
HC Wainwright Lifts Earnings Estimates for Orchestra BioMed
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AMH Equity Ltd Buys New Position in Orchestra BioMed Holdings, Inc. $OBIO
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)